HCV
  • Featured content
    Eliminating HCV infection among persons who inject drugs is a daunting task whether tackling it from a patient care perspective, through practice transformation, or by influencing policies that improve access to treatment. Nonetheless, there are practical steps that can be taken by clinicians to improve the HCV continuum of care for this challenging population. Here’s my take on some of those steps.
    Date Posted: 1/19/2018
  • Featured content
    Listen to downloadable audio from a series of live Webinars by Stephen A. Harrison, MD, COL (Ret.), FAASLD; Paul Y. Kwo, MD; and Norah Terrault, MD, MPH, FAASLD, in which the clinical impact of new data reported at the Washington, DC meeting is discussed.
    Date Posted: 11/20/2017
  • Featured content
    With the approvals of SOF/VEL/VOX and GLE/PIB, what is the new management approach for DAA-experienced patients with HCV infection?
    Date Posted: 11/16/2017
  • Featured content
    What parameters now qualify a patient infected with HCV for shortened first-line therapy?
    Date Posted: 11/15/2017
  • Featured content
    Listen to downloadable audio from a series of live Webinars by Jordan J. Feld, MD, MPH; Nancy Reau, MD, FAASLD, AGAF; and Stefan Zeuzem, MD, in which the impact of recently approved direct-acting antiviral regimens for treatment-naive patients with HCV is discussed.
    Date Posted: 11/15/2017
  • 1
  • 2
  • 3
  • 4
  • 5

Latest Content

10 of 361 Shown
  • Adopting Strategies to Eliminate HCV in Persons Who Inject Drugs

    Frederick L. Altice MD - 1/19/2018
    Eliminating HCV infection among persons who inject drugs is a daunting task whether tackling it from a patient care perspective, through practice transformation, or by influencing policies that improve access to treatment. Nonetheless, there are practical steps that can be taken by clinicians to improve the HCV continuum of care for this challenging population. Here’s my take on some of those steps.
  • Interactive Virtual Presentation cme-icon

    Hepatitis C Update: A Growing Challenge With Evolving Management Solutions

    In this updated CME-certified interactive presentation targeted to primary care clinicians, hepatitis expert Terry D. Box, MD, reviews the changing epidemiology of hepatitis C infections, age- and risk-based HCV screening, follow-up after testing in the primary care and specialist settings, and counseling patients on the benefits of HCV screening and treatment.
    Faculty: Terry D. Box MD, Brian L. Pearlman MD, FACP, FAASLD, Mary Speigle NP
    Released: 1/17/2018
  • How New Data From AASLD 2017 Inform the Use of 8-Week Regimens for HCV

    Ira M. Jacobson MD - 1/9/2018
    How will data presented at AASLD 2017 on 8-week therapy have an impact on management of patients with HCV infection? Here’s my take.
  • How Injection Drug Use Affects HCV Treatment

    Norah Terrault MD, MPH - 1/3/2018 1 comment / Last Comment: 1/16/2018
    Here’s my take on why colocalization of HCV treatment with other medical and social services may be ideal for persons who inject drugs.
  • Hepatitis Alert: HCV Elimination—Closing the Gaps in Screening, Care Linkage, and Treatment

    Listen to downloadable audio from a series of live Webinars in which expert faculty review important strategies for closing gaps along the HCV care continuum with a focus on overcoming barriers to reach and treat persons who inject drugs.
    Date Posted: 1/2/2018
  • Hepatitis Alert: HCV Elimination—Closing the Gaps in Screening, Care Linkage, and Treatment

    In this downloadable slideset, Norah Terrault, MD, MPH, and Stacey Trooskin, MD, PhD, review important strategies for closing gaps along the HCV care continuum with a focus on overcoming barriers to reach and treat persons who inject drugs.
    Date Posted: 12/19/2017
  • HCV Prevention in Correctional Settings Is Good Medicine

    Lara Strick MD, MS - 12/12/2017 2 comments / Last Comment: 1/16/2018
    Implementation of prevention services targeting incarcerated patients is possible. Let me tell you why.
  • Extending HCV Care Past Cure to Prevent Reinfection in High-Risk Populations

    Christian B. Ramers MD, MPH - 11/30/2017
    With long-term health and wellness as a framing principle, curing HCV is not the finish line but rather a starting point for a conversation about maintaining wellness, preventing progression of liver disease, addressing harmful drug and alcohol habits, and, of importance, preventing HCV reinfection.
  • Video Module cme-icon ce-icon

    A Call to Arms: Tools for HCV Treaters to Maximize HCV Cure Rates and Advance Toward HCV Elimination

    Led by Norah Terrault, MD, MPH, a panel of experts including Jordan J. Feld, MD, MPH; Ira M. Jacobson, MD; Paul Y. Kwo, MD; and Christian B. Ramers, MD, MPH, provides an overview of the current state of HCV therapy, with an emphasis on the most recently approved options, and discusses 3 important focal points for achieving HCV elimination goals: increasing screening and diagnosis, treating populations that previously have been excluded from therapy, and curing the small but challenging population of patients who have experienced previous failure of direct-acting antiviral therapy.
    Faculty: Jordan J. Feld MD, MPH, Ira M. Jacobson MD, Paul Y. Kwo MD, Christian B. Ramers MD, MPH
    Released: 11/27/2017
  • Key Studies Influencing My Practice Following Washington 2017

    Listen to downloadable audio from a series of live Webinars by Stephen A. Harrison, MD, COL (Ret.), FAASLD; Paul Y. Kwo, MD; and Norah Terrault, MD, MPH, FAASLD, in which the clinical impact of new data reported at the Washington, DC meeting is discussed.
    Date Posted: 11/20/2017
10 of 361 Shown
Show 10 More
Loading...